Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
Genetically modified T cell therapy using chimeric antigen receptor (CAR) (CAR - T therapy) has been shown to be promising as a new cancer treatment method, and application to various cancers is expected. In this study, we developed a piggyBac transposon vector for novel chimeric antigen receptor genetically modified T cells for the antigen expressed on osteosarcoma cells and our culture method enabling high transduction efficiency using the piggyBac transposon gene transfer method. The novel CAR-T cells in this study exerted potent killing activity against osteosarcoma cells. Based on this study, we could obtain baseline data of novel immunotherapy for osteosarcoma.
|